Cellular adhesion and the endothelium: P-selectin

Abdullah Kutlar, Stephen H. Embury

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

P-selectin on endothelial cell surfaces is central to impaired microvascular blood flow in sickle cell disease (SCD). Restoration of blood flow is expected to provide therapeutic benefit for SCD patients, whatever the mechanism of action of the treatment. Long-term oral administration of a P-selectin-blocking agent potentially improves blood flow and averts acute painful vaso-occlusive crises in patients with SCD. This review focuses on the pathophysiology of the impairment of microvascular blood flow in SCD with an emphasis on the role of P-selectin and summarizes the status of development of antiselectin therapies as a means of improving microvascular flow.

Original languageEnglish (US)
Pages (from-to)323-339
Number of pages17
JournalHematology/Oncology Clinics of North America
Volume28
Issue number2
DOIs
StatePublished - Apr 1 2014

Fingerprint

P-Selectin
Sickle Cell Anemia
Endothelium
Oral Administration
Therapeutics
Endothelial Cells

Keywords

  • Impaired blood flow in sickle cell disease
  • Microvascular occlusion
  • P-selectin
  • Pentosan polysulfate sodium
  • Sickle cell disease
  • Sickle red cell adhesion

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Cellular adhesion and the endothelium : P-selectin. / Kutlar, Abdullah; Embury, Stephen H.

In: Hematology/Oncology Clinics of North America, Vol. 28, No. 2, 01.04.2014, p. 323-339.

Research output: Contribution to journalReview article

@article{23746bed4e704e05be4e136f03605281,
title = "Cellular adhesion and the endothelium: P-selectin",
abstract = "P-selectin on endothelial cell surfaces is central to impaired microvascular blood flow in sickle cell disease (SCD). Restoration of blood flow is expected to provide therapeutic benefit for SCD patients, whatever the mechanism of action of the treatment. Long-term oral administration of a P-selectin-blocking agent potentially improves blood flow and averts acute painful vaso-occlusive crises in patients with SCD. This review focuses on the pathophysiology of the impairment of microvascular blood flow in SCD with an emphasis on the role of P-selectin and summarizes the status of development of antiselectin therapies as a means of improving microvascular flow.",
keywords = "Impaired blood flow in sickle cell disease, Microvascular occlusion, P-selectin, Pentosan polysulfate sodium, Sickle cell disease, Sickle red cell adhesion",
author = "Abdullah Kutlar and Embury, {Stephen H.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1016/j.hoc.2013.11.007",
language = "English (US)",
volume = "28",
pages = "323--339",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Cellular adhesion and the endothelium

T2 - P-selectin

AU - Kutlar, Abdullah

AU - Embury, Stephen H.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - P-selectin on endothelial cell surfaces is central to impaired microvascular blood flow in sickle cell disease (SCD). Restoration of blood flow is expected to provide therapeutic benefit for SCD patients, whatever the mechanism of action of the treatment. Long-term oral administration of a P-selectin-blocking agent potentially improves blood flow and averts acute painful vaso-occlusive crises in patients with SCD. This review focuses on the pathophysiology of the impairment of microvascular blood flow in SCD with an emphasis on the role of P-selectin and summarizes the status of development of antiselectin therapies as a means of improving microvascular flow.

AB - P-selectin on endothelial cell surfaces is central to impaired microvascular blood flow in sickle cell disease (SCD). Restoration of blood flow is expected to provide therapeutic benefit for SCD patients, whatever the mechanism of action of the treatment. Long-term oral administration of a P-selectin-blocking agent potentially improves blood flow and averts acute painful vaso-occlusive crises in patients with SCD. This review focuses on the pathophysiology of the impairment of microvascular blood flow in SCD with an emphasis on the role of P-selectin and summarizes the status of development of antiselectin therapies as a means of improving microvascular flow.

KW - Impaired blood flow in sickle cell disease

KW - Microvascular occlusion

KW - P-selectin

KW - Pentosan polysulfate sodium

KW - Sickle cell disease

KW - Sickle red cell adhesion

UR - http://www.scopus.com/inward/record.url?scp=84896722398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896722398&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2013.11.007

DO - 10.1016/j.hoc.2013.11.007

M3 - Review article

C2 - 24589269

AN - SCOPUS:84896722398

VL - 28

SP - 323

EP - 339

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -